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1. Introduction 
In 1968, hematopoietic stem cell transplantation (HSCT) was first performed for patients 
with inherited cellular immunodeficiencies: a child with severe combined immune 
deficiency (SCID) and another with Wiskott–Aldrich syndrome (WAS) transplanted from 
matched siblings [1, 2]. Since then, HSCT techniques have advanced enormously due to 
refined HLA-tissue typing, the increased use of alternative donors, the availability of new 
stem cell sources including umbilical cord blood as well as less toxic chemotherapeutic 
conditioning [3], and graft-versus host disease (GVHD) prophylaxis. Supportive care has 
also improved, with molecular detection of viral infection enabling pre-emptive antiviral 
treatment before organ damage supervenes [4]. Greater awareness of primary 
immunodeficiency (PID) amongst general paediatricians, highlighted by campaigns 
promoting warning signs has lead to earlier diagnosis and referral to specialist centres[5]. 
Indications for HSCT increase as advances in molecular immunology better define PIDs 
while parallel studies of the natural history of PIDs reveal which will benefit most from 
early HSCT before organ damage is present[6]. There are now nearly 200 molecularly 
defined PIDs. HSCT aims to give stable donor stem cell engraftment after partial or full 
ablation of the recipient’s marrow and immune system using a combination of 
chemotherapy, antibody therapy, and a graft-versus-marrow effect. [7] Nearly 1,500 
children in Europe who have received allogeneic HSCT for PIDs[8] were reported 
recently, as well as over 1,000 children from Northern America in 2008.[9] Overall 
survival has increased to 90% for SCID babies with a genoidentical donor and nearly 70% 
for those given matched unrelated donor (URD) HSCT. For non-SCID PIDs, the survival 
for both genoidentical and URD HSCT is between 70% and 80%.[8] Together with 
improved survival advances have led, and continue to focus on, improved quality of life 
longterm. 
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2. Who, when, what to transplant 
SCID is one of the most severe forms of PID. Early diagnosis and management are essential 
and HSCT is curative. For other forms of PID, management and in particular the indications 
for HSCT are evolving. New data is emerging on the natural history of patients with 
diseases such as CGD and CD40L deficiency and the outcome from HSCT has improved 
dramatically and so the risks of performing HSCT at a young age before organ damage from 
recurrent infection and inflammation need to be carefully assessed and discussed with 
families balanced against a potentially shortened life span with poor quality of life due to 
multiple hospital admissions. 
Table 1 gives a current list of primary immunodeficiency diseases in which HSCT is 
indicated. 
2.1. Importance of molecular diagnosis 
Precise molecular diagnosis is very helpful as prognosis can then be accurately assessed. 
The outcome following HSCT for patients with B negative forms of SCID such as RAG 
deficiency is less good than for those with B positive forms. Furthermore those with artemis 
deficiency have a worse prognosis than those with RAG deficiency because of the associated 
cellular radiosensitivity. In the long term post HSCT human papilloma virus warts 
predominantly occur in patients with common gamma chain or JAK3 deficient SCID[10], 
but not other SCID genotypes. 
Ill-defined combined immunodeficiencies (CID) are a challenge to treat, as the outcome with 
HSCT is variable, and often poor[8]. This is because, at least in part, decisions about when to 
transplant are not made until a disease-defining illness has occurred (Table 2), which may 
leave significant organ damage or a persisting viral burden, which alters the prognosis 
following transplantation. Identification of a specific gene defect in a patient cohort can alter 
management decisions. For example, clear molecular definition has changed the 
management of an autosomal recessive form of hyper IgE syndrome caused by mutations in 
the dedicator of the cytokinesis 8 (DOCK8) gene. Previously this disease was managed 
conservatively, as a form of hyper IgE syndrome. Accurate molecular definition enabled 
data to be gathered on a patient cohort leading to the realisation that there is a high risk of 
infection, skin malignancy and death.  Reports of cases being successfully transplanted have 
lead to HSCT becoming the treatment of choice for this diagnosis.[11-15] 
Reticular dysgenesis is an autosomal recessive form of SCID characterised by an early 
differentiation arrest in myeloid lineage and impaired lymphoid maturation. Affected 
individuals also have bilateral sensorineural deafness. Mutations in AK2 (adenylate kinase 
2) published in 2008 demonstrated that AK2 is expressed in the stria vascularis region of the 
inner ear providing an explanation for the deafness in addition to it’s role in specific 
haematopoietic lineages. Again this can lead to an earlier specific diagnosis and appropriate 
intervention.[16]  
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Abbreviations: CγC Common gamma chain, XL X linked, Jak 3 Janus associated kinase 3, AR Autosomal recessive, 
ADA Adenosine deaminase, RAG Recombinant activating gene, MHC Major histocompatibility, PNP Purine 
nucleoside phosphorylase, IPEX Immunodeficiency polyendocrinopathy enteropathy X linked, CHARGE coloboma, 
heart anomalies, choanal atresia, retardation of growth and development, and genital and ear anomalies due to CHD7 
gene mutations. 
*Thymic transplant recommended in preference to HSCT 
**Not all require HSCT 
Table 1. Indications for HSCT in immunodeficiencies 
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2.2. Severe combined immunodeficiency 
Severe combined immunodeficiency is usually fatal by 1 year of age unless an infant 
receives a new immune system and should be considered a paediatric emergency which is 
immediately life threatening. In the most recent analysis of 699 SCID patients transplanted 
across Europe there was a survival of 90% for those transplanted with a genoidentical 
sibling donor and nearly 70% for those receiving a matched unrelated donor[8]. The 
outcome for those without pre-existing infection such as those diagnosed at birth is even 
better: in the UK series the survival for those transplanted having being diagnosed at or 
before birth was 91.5% compared to 61% for those transplanted having being diagnosed at a 
median age of 143 days and a significant number of these children died from infection 
before reaching transplant[5]. These data support neonatal screening programmes, which 
are being introduced in North America, and pick up patients with SCID in the newborn 
period, before infection supervenes[17]. Similar screening programmes are being considered 
in Europe. Recognition of the specific molecular defect may alter the approach to HSCT. 
Patients with adenosine deaminase-deficient SCID will develop adequate immunological 
reconstitution following an unconditioned infusion from HLA-identical sibling stem 
cells[18], whereas those with RAG-deficient SCID will require chemotherapy conditioning 
to achieve stem cell engraftment and immunological reconstitution. 
2.3. Other primary immunodeficiencies 
For other non-SCID PID, debate continues about the optimum age for transplantation. As 
registry data for specific diseases becomes available, the role of HSCT is increasingly clear, 
but the optimum age for transplantation remains to be determined. Earlier transplantation is 
favoured for T cell immunodeficiencies.  
Filipovich et al published results of 170 transplants for Wiskott Aldrich syndrome and 
demonstrated that boys receiving an unrelated donor transplant before the age of 5 had as 
high a survival rate to matched sibling donor recipients of any age[19]. A recent 
international report of 194 patients with Wiskott Aldrich syndrome, transplanted in 12 
centers, reported an overall survival of 84%, rising to 89% for those transplanted since the 
year 2000. Younger age and milder clinical phenotype was associated with better 
outcome[20]. Whilst survival has improved over the last decade, young age at transplant 
before complications of the underlying disease supervene, also improves outcome.[21]  
The outcome of patients transplanted for CD40 ligand deficiency is also dependent on age at 
transplantation, with pre-existing lung disease being a significant factor in predicting 
survival[22, 23]. Thirty eight children were reported who were transplanted in Europe for 
CD40L between 1993 and 2002. Of the 34 engrafted, 26 survived (68%), and 20 no longer 
required immunoglobulin replacement therapy. This survival and cure rate was little better 
than the survival of non-transplanted patients at the age of 20 years. However, many 
patients in this series were over 10 years of age when transplanted and already had 
significant lung and/or liver damage. A total of 14 patients with CD40L deficiency have been 
transplanted in our centre: 2 received MSD and 10 URD; 4 died (overall survival 71%), but 
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none since the year 2000, and 3 out of the 4 deaths were in children over 12 years of age who 
already had sclerosing cholangitis. All the survivors express CD40L and only one needs 
immunoglobulin. These data further emphasize the importance of early age at transplant 
before organ damage supervenes. 
For non-T cell immunodeficiencies, timing of transplantation has been more controversial, 
although with registry data becoming available, the natural history of disease on 
conventional treatment is becoming more clear. Lifelong antibacterial and antifungal 
prophylaxis with cotrimoxazole and itraconazole has improved short- and medium-term 
survival for patients with chronic granulomatous disease. However, although steroids and 
aminosalicylates ameliorate colitis and other inflammatory complications they do not cure 
the underlying genetic defect and longterm immunosuppression is required to maintain 
symptom control. Quality of life is poor with frequent hospital admissions and poor growth. 
Even with the best prophylactic treatment, only 50% of patients are alive at 30 years[6] 
(Figure 1). HSCT can cure CGD with resolution of infection and colitis but was previously 
considered to be a high risk procedure. A European multicenter experience of replete 
marrow HSCT with mainly matched sibling donor stem cells following myeloablative 
conditioning gave good results; 23/27 patients survived, 22 were cured (81%), with deaths 
confined to high-risk patients with active fungal infection[24]. A more recent single centre 
study demonstrated similar outcomes with either matched sibling or matched unrelated 
donors, with a survival and cure of 90% and low incidence of significant GvHD. Mean 
weight and height for age Z scores on recovery from HSCT rose significantly. Transplant-
associated complications were restricted to those with pre-existing infection or 
inflammation, supporting the argument for early HSCT for all CGD patients with a well 
matched donor[25]. As transplantation techniques improve, and survival increases, earlier 
transplantation becomes a more attractive option for other primary immunodeficiencies 
requiring long term antimicrobials and immunosuppression to control symptoms. 
2.4. Donor choice and degree of HLA matching 
Unlike patients with haematological malignancy in whom a graft versus leukaemia effect is 
desirable, GVHD confers no benefit to patients with PID. The best HLA matched donor is a 
sibling and so any siblings of the patient should be tissue typed. Many PID patients come 
from consanguineous families and so it may be possible to find a donor from the extended 
family. When tissue typing reveals more than one possible donor, other factors such as age, 
sex, parity, blood group and cytomegalovirus (CMV) status are taken into consideration. If 
no family donor is found a search of the National and International unrelated donor 
registries should be undertaken. There are currently 19 million adult and over 500,000 cord 
blood donors that can be accessed through the Bone Marrow Donors Worldwide registry 
(www.bmdw.org). 
3. Stem cell source 
Bone marrow has been the traditional source of stem cells and is harvested under general 
anaesthetic from the posterior iliac crests. Adult donors are increasingly being offered the 
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option of donating peripheral blood stem cells (PBSC) rather than bone marrow.  This may 
be especially useful for donors who may have a medical condition of their own that would 
increase the risks of general anaesthesia. PBSC collection is generally carried out as a day 
case procedure and some donors find this prospect less difficult than the short period of 
hospitalisation and general anaesthetic needed for bone marrow donation.  However, PBSC 
will require the donor to receive a short course of injections of granulocyte-colony 
stimulating factor (G-CSF) prior to commencing the first collection.  Typically G-CSF at 10 
micrograms per kilogram is given daily for 5 days before 1-2 leukapheresis procedures are 
performed.  This procedure is not licensed in children in most countries and so sibling 
donations from children continue to be bone marrow. 
 
(Permission granted from Jones, et al6. Copyright by John Wiley and Sons, Ltd.) 
Figure 1. Kaplan–Meier survival estimates, by sex for UK patients with chronic granulomatous disease.  
Umbilical cord blood stem cell transplantation (UCSCT) offers a stem cell source when a 
matched sibling donor is unavailable. 
Advantages of UCSCT include 
i. quick access to the cord blood unit and ease of arranging date of transplant 
ii. absence of risk to donor 
iii. lower risk of latent viral transmission and graft versus host disease (GvHD) 
iv. higher chance of matching rare HLA haplotypes.  
Additionally, the HSC telomere length is longer in patients who have received UCSC than 
in those who have received PBSC from older donors. UCSCs may have greater self renewing 
capacity and longevity than those derived from an adult donor.  As many transplanted PID 
patients are infants or young children, giving HSC with a greater proliferative life span is 
theoretically more attractive. 
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Disadvantages of UCSCT include 
i. low stem cell dose, particularly for an older child,  
ii. Lack of availability of the donor should any boost procedure be required  
iii. Cord blood units are virologically naïve and have been reported to have slower 
engraftment which increases the risks from pre-existing infections.  
However, the conditioning regimen employed may influence this, as omission of 
serotherapy enables viral clearance, albeit with an increased risk of GvHD[26]. 
For PID patients who often present before 1 year of age, UCSCT can offer a suitable stem cell 
source. In a recent European study mismatched-related donor HSCT was compared to  
unrelated donor cord HSCT in children with severe T cell deficiencies. There was no 
significant difference in survival, but cord blood recipients had a higher frequency of 
complete donor chimerism at day 100 and faster total lymphocyte recovery.[27]  
4. Assessment of donor 
A Physician or Paediatrician who is independent to that of the recipient should perform a 
pre-transplant assessment of any family donor. A medical history should be taken 
including: 
• Vaccination history  
• blood transfusion history 
• allergy history  
• history of travel to tropical countries  
• number of pregnancies in women  
A routine physical examination is performed and a chest radiograph and ECG if indicated.  
For unrelated donors the examination is performed by the donor assessment centre. 
However the transplant centre will need to request blood for confirmatory tissue typing, 
DNA analysis for post transplant chimerism studies and the opportunity is usually taken to 
check the donor virology and serology status. The donor’s fitness to donate must be 
ascertained before conditioning of the patient begins. The donor centre is responsible for the 
consent of the donor. The donor needs to be fully informed about the procedure for collecting 
the stem cells, the blood tests that will be performed including HIV status, the possibility of a 
second donation for the same patient and the emphasis on anonymity for the donor and 
patient. Anonymity may be relaxed in time and regulations may vary in different countries. 
For related donors in the UK in addition to a physical examination, under the Human Tissue 
Act 2004, any potential donation of bone marrow or PBSC from adults who lack capacity to 
consent and children who lack competence to consent, must be assessed by an Accredited 
Assessor and a report submitted to the Human Tissue Authority for consideration. 
Psychological aspects for the donor are important particularly when children are donating 
for siblings, for example if the recipient does not survive the donor may feel it is their fault. 
Therefore preparation and counselling for the donor is important 
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For cord blood donations at the time of cord collection tests for the following are performed 
on the mother: 
The current minimum serology testing requirements for these products are summarised 
below: 
Anti-HIV-1,2 
HBsAg  
Anti HBc (hepatitis B core antibody) 
Anti-HCV-Ab (anti-hepatitis C antibody) 
A validated testing algorithm to exclude the presence of syphilis/active infection  
with Treponema pallidum (Anti-T. pallidum) 
HTLV-I antibody testing for maternal donors living in, or originating from, high-incidence 
areas or with sexual partners originating from those areas, or where the donor’s parents 
originate from those areas.                            
Furthermore, if the cord blood unit has been stored for more than 180 days the additional 
testing is required: 
Nucleic acid testing for HIV (HIV-NAT) 
Nucleic acid testing for hepatitis B (HBV-NAT) 
Nucleic acid testing for hepatitis C (HCV-NAT) 
Nucleic acid testing for HTLV-I (HTLV-I-NAT) of maternal donors living in, or originating 
from, high-incidence areas or with sexual partners originating from those areas, or where 
the donor’s parents originate from those areas.   
Confirmatory tests 3 to 6 months after delivery are also performed. The health of the baby is 
also assessed. Cord blood banks will supply the transplant centre with the required viral 
status of the mother and sometimes the cord blood itself. The cell doses contained within the 
cord donation and cell viability are also recorded. They will also perform extra tests for 
confirmatory tissue typing and virology and serology on small aliquots of the cord. Some 
centres may wish to perform their own confirmatory typing. A small sample is usually 
taken at the time of thawing for DNA analysis for post transplant chimerism studies. 
5. Preparation of patient 
The clinical condition of patients undergoing stem cell transplantation varies enormously 
depending on diagnosis, age, previous treatment, and organ damage. Once the decision to 
transplant has been made and a donor selected each organ system should be assessed so that 
any organ damage is known about prior to transplant and therefore potential harmful effects 
of chemotherapy, risks for GVHD and recurrence of infections can be anticipated. A full 
medical history should be taken and a physical examination performed. It is useful to perform 
the assessment at least 6 weeks before the transplant date in order that any necessary 
investigations can be arranged. A checklist is essential (Figure 2). It is helpful to perform 
microbiology screening for resistant bacteria e.g. methicillin resistant staphylococcus aureus 
(MRSA) and glycopeptide resistant enterococci (GRE/VRE). This will depend on unit policy. 
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With permission from Kath Grey. Liaison team nursing sister. Great North Children’s Hospital, Newcastle upon Tyne 
Figure 2. Checklist for patients requiring an immunology assessment for HSCT 
A number of infectious agents, particularly viruses, can now be detected by sensitive 
molecular techniques such as polymerase chain reaction (PCR) at an early stage of the 
infectious process. This in turn means that pre-emptive therapy can be given before organ 
damage such as life threatening pneumonitis or hepatitis, occurs. Such early detection 
together with treatments such as cidofovir for Adenovirus has led to a dramatic 
improvement in outcome following viral infection. 
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Many children with PID fail to thrive and are malnourished and it is important to maximise 
nutritional status prior to transplant, which may mean high calorie enteral feeding via 
nasogastric tube or parenteral nutrition through a central venous catheter. 
Some diseases such as IPEX syndrome require immunosuppression to control autoimmune 
enteropathy and it is important to suppress any active inflammation prior to transplant, but 
also to minimise immunosuppression in order to reduce risk of infection. 
Familial haemophagocytic lymphohistiocytosis is a genetically determined disorder 
characterized by the early onset of fever, hepatosplenomegaly, central nervous system 
disease, thrombocytopenia, coagulation disorders, and haemophagocytosis. It is caused by 
genetic defects that impair T cell–mediated and natural cytotoxicity. Chemotherapy and/or 
immunotherapy-based treatments can achieve remission, but HSCT is the only curative 
option. Outcome of HSCT is much more favourable if active disease is controlled prior to 
transplantation[28]. 
Sometimes a combination of antimicrobials and immunosuppression may be the optimal 
treatment. For example, Leiding et al have described 9 cases of severe life threatening liver 
abscesses in patients with CGD that progressed despite appropriate antibacterial therapy 
and drainage but responded to moderately high doses of corticosteroids tapered over 
several months.[29] 
It is essential to address family and psychosocial issues and so each patient should be 
referred to a social worker and psychologist. Each unit will have their own system for 
information giving including written information about the transplant procedure, a visit to 
the unit and a home visit. It may be appropriate for patients to meet the dietician and 
physiotherapist prior to transplant. Fertility issues need to be discussed. In particular sperm 
banking should be arranged if appropriate. It is vital that written consent is taken once the 
patient/family are fully aware of all the aspects of the transplant. 
6. Conditioning 
Conditioning aims to create space in the recipient marrow niche to enable donor stem cells 
to engraft more easily. A range of conditioning regimens are available from non conditioning, 
through immunosuppressive regimens to myeloablative combinations (Figure 3). 
For many years, myeloablative chemotherapy with busulphan and cyclophosphamide was 
given prior to HSCT for PIDs. However, busulphan is associated with significant toxicity 
including veno-occlusive disease (VOD). A strong correlation between blood levels of 
cyclophosphamide metabolites and VOD has previously been shown due to depletion of 
glutathione from the liver[30]. Combinations of cyclophosphamide with reduced-dose 
busulphan may also lead to severe hepatic toxicity and VOD [31, 32]. The combination of 
fludarabine and full dose busulfan has gradually replaced the combination of busulfan and 
cyclophosphamide in most centres. Malar et al. have recently reported on the importance of 
therapeutic drug monitoring for intravenous busulphan therapy in 34 paediatric patients. 
Seven children all weighing less than 12 kg had VOD despite not exceeding the targeted 
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area under the curve: six of them had AUCs below the target range, highlighting the 
difficulty in giving busulphan to this young group of children despite careful therapeutic 
monitoring.[33]  
 
Figure 3. Chemotherapy regimens, increasing in intensity from left to right 
Reduced-intensity conditioning regimens using drugs such as fludarabine and melphalan 
have diminished treatment-related toxicity in some PID patients,[3] but toxicity remains a 
problem for children under one year of age,[34] and cardiac toxicity is associated with 
melphalan[35]. Minimal-intensity conditioning with fludarabine and low dose 
cyclophosphamide can reduce toxicity even further, but may be associated with poor donor 
myeloid chimerism or an increased incidence of GVHD.[36] Consequently, new 
conditioning regimens for PIDs have been developed that give adequate myeloablation but 
less toxicity, particularly in patients under one year of age. Treosulfan (l-treitol-1, 4-bis-
methanesulfonate) is the pro-drug of l-epoxybutane, a water-soluble bifunctional alkylating 
agent with myeloablative and immunosuppressive properties,[37] and is effective in HSCT 
conditioning with less toxicity, particularly in VOD, compared to busulphan. A recent study 
of 70 children in the UK, transplanted for various PIDs and given treosulfan with either 
fludarabine or cyclophosphamide, showed an overall survival of 81%. Of 46 children less 
than 12 months of age at HSCT, only eight died (overall survival 83%). Two children had 
VOD when treosulfan was given in combination with cyclophosphamide, but none when it 
was given with fludarabine. In the treosulfan cohort, there was no cardiactoxicity, such as 
seen with melphalan or pulmonary fibrosis as seen with busulphan[38-40]. T cell chimerism 
was significantly better when treosulfan was given in combination with fludarabine, and 
although numbers were small, there was a suggestion that chimerism was better when 
PBSCs were used as the stem source. Conversely, patients receiving cord blood stem cells in 
conjunction with serotherapy had a tendency to more mixed donor chimerism. While donor 
myeloid chimerism was sufficiently high to cure most patients with CGD and WAS with all 
donor types/stem cell sources, where 100% donor chimerism might be preferred in all cell 
lineages—for example, WAS[20] — then the use of PBSCs or full myeloablation with 
busulphan might be required. Early results using PBSCs with treosulfan and fludarabine 
look promising in terms of good chimerism without an increased incidence of greater than 
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grade II GVHD. Prospective studies are needed comparing treosulfan/ fludarabine with 
busulphan and fludarabine,[41-43] where early reports also indicate reduced transplant-
related toxicities and excellent survival. Long-term follow-up is needed to see if this 
“modified intensity” regimen results in less long-term toxicity and, in particular, infertility, 
as the gonadal toxicity of busulphan is already well documented[44]. Radioimmunotherapy, 
in which targeted irradiation of the bone marrow is achieved by using radiolabeled 
monoclonal antibodies, may be used as a potent myeloablative agent with low intrinsic 
organ toxicity. Schulz et al. recently reported on the use of radioimmunotherapy with 90Y-
anti-CD66 for conditioning in 30 pediatric patients undergoing HSCT, including 16 with 
non-malignant disorders with high co-morbidities. Patients received radioimmunotherapy 
with fludarabine or melphalan alone or in combination, usually with ATG; one patient was 
given radioimmunotherapy alone. A highly favorable ratio of marrow dose to other organ 
dose was demonstrated, and stable engraftment was achieved with complete donor 
chimerism in 13 out of 16 (81%) patients. One patient with Griscelli syndrome and who had 
secondary graft failure after the first HLA haploidentical transplantation achieved stable 
complete donor chimerism with radioimmunotherapy alone[45]. 
Antibodies to eliminate host stem cells prior to transplantation could mean that toxic 
conditioning regimens would not be needed. Administration of ACK2 and an antibody that 
blocks c-Kit function led to transient removal of >98% of endogenous HSCs in immune-
deficient mice[46].  Subsequent transplantation with donor HSCs led to chimerism levels up 
to 90% compared to only 3% in those without this preconditioning. The pharmacological 
agent AMD3100, which is a CXCR4 inhibitor, has been shown to induce egress of HSCs out 
of the marrow and improve levels of donor HSC engraftment relative to untreated 
recipients[47]. Plerixafor, a CXCR4 inhibitor, may also be a more effective mobilizer of stem 
cells for donors of PBSCs than granulocyte colony stimulating factor (G-CSF), allowing 
larger doses of stem cells to be administered, which may lead to more rapid engraftment. 
7. Methods of T cell depletion 
In 1981 the introduction of T lymphocyte depletion to remove of alloreactive lymphocytes 
from the bone marrow source enabled transplantation across HLA barriers.  This meant that 
patients without an HLA-identical donor could receive T lymphocyte depleted marrow 
from an HLA-haploidentical parent.   
Profound T-cell depletion is a fundamental prerequisite for haploidentical donor 
transplantation to avoid severe GVHD and B cell depletion lessens the risk of Epstein Barr 
Virus (EBV)-related lymphoproliferative disease. Various methods have been used to 
remove viable T lymphocytes from the graft, including E-rosette lectin depletion and in 
vitro anti CD52 (CAMPATH-1M anti-lymphocyte antibody which is no longer available). 
Since the late 1990s European centers performing T lymphocyte–depleted HSCT for patients 
with PID have used CD34+ stem cell selection rather than T-lymphocyte depletion. The most 
commonly used method, the Miltenyi Clini-MACS system, uses an organic iron bead 
attached to an anti-CD34 antibody to isolate purified CD34+ HSCs from the other cells by 
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passing the HSC source through a magnetic column[48]. The purified CD34+ HSC fraction is 
infused into the patient. By using this method, 4 log depletions of T-lymphocyte numbers 
can be achieved. There are important differences between CD34+ stem cell–selected and T 
lymphocyte–depleted bone marrow. Although the residual T-lymphocyte count in anti-
CD52–treated marrow can be relatively high, very few of the T lymphocytes remain viable 
because they are still coated with anti-CD52 when infused into the recipient and are then 
destroyed by complement-mediated lysis. In the anti-CD34 selected HSC product, although 
the number of T lymphocytes infused into the patient might be very low, those that are 
infused are viable and could cause GvHD. The anti-CD52– treated product contains 
component blood cell precursors and cells already in early differentiation from the stem cell, 
as well as other stromal factors that might aid engraftment of HSCs into the bone marrow 
space thus achieving better engraftment. 
An alternative means of stem cell enrichment has been used with the aim of achieving an 
optimal balance between the competing risks of GVHD, poor engraftment and delayed 
immune reconstitution. By targeting T- and B- cells specifically CD3/CD19 depleted grafts 
not only retain CD34+ stem cells but also CD34 negative progenitors, natural killer, 
dendritic and graft-facilitating cells which enhance engraftment. 
Further developments are now focusing on the depletion of TcRαβ+ T cells which can 
prevent GvHD after allogeneic stem cell transplantation from HLA non identical donors and 
may lead to more rapid immune reconstitution than CD3+ depletion of grafts.  In contrast to 
depletion of CD3+ T cells valuable TcRγδ+ T cells are spared.[49] 
8. Results 
8.1. Severe combined immunodeficiency 
A successful HSCT procedure in patients with primary immunodeficiency should result in a 
cure of the underlying defect with normal immuno-reconstitution leading to normal 
immune function and a normal life. The likelihood of a successful outcome depends on the 
underlying diagnosis, degree of HLA matching from the donor, and pre existing end organ 
damage. Overall the outcome for patients with SCID is better than that for patients with 
other PID and has improved over time[8]. The likelihood of cure following HSCT is up to 
90% in those SCID patients with a genoidentical donor. Even for those with no HLA 
identical donor, survival following a T cell depleted haploidentical transplant is 
approaching 60%. Whilst infusion of the stem cell product without the use of chemotherapy 
eliminates the potentially fatal effects of conditioning including infection from aplasia and 
increased risk of pneumonitis and mucositis, the quality of engraftment is compromised. 
Thus for patients with common gamma chain or JAK3 SCID thymopoiesis may be achieved 
as T cell precursors engraft in the thymus[50], but B cell engraftment is unlikely and patients 
will remain on lifelong immunoglobulin replacement as recipient B cells are unable to 
produce IgM through the IL 21 mediated signalling path and do not undergo 
immunoglobulin class switching.[51]  Patients thus remain at risk of bronchiectasis in the 
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long term. However, for patients with VDJ recombination defects leading to T- B-NK+ SCID, 
stem cell infusion will lead to no B cell engraftment and only peripheral T cell engraftment 
with poor T cell numbers, no thymopoiesis and risk of immunosenescence in the medium 
term.[52]. So, although conditioning may increase the short term risks, immune function is 
better in the long term following chemotherapy. Full donor chimerism is not necessary as 
stable mixed donor chimerism may give adequate immune reconstitution. Best results are 
achieved in patients diagnosed early with no infection and no end organ damage. Newborn 
transplantation gives the best results of all[5, 53, 54], giving weight to the argument for 
newborn screening by detection of T cell receptor excision circles (TRECS) on the neonatal 
blood spot (Guthrie) card and thus detection of SCID before presentation with a SCID 
defining illness such as pneumocystis pneumonitis (Table 2).  
 
Table 2. Disease defining illness in Primary Immunodeficiency 
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For those patients presenting late with infection, graft manipulation such as new methods of 
T cell depletion and add back of virus specific cytotoxic T cells has enabled more rapid 
immunoreconstitution and viral clearance[55]. For those patients requiring additional 
support through the transplant period, improvement in paediatric intensive care, close 
liaison between BMT and PICU teams, and earlier interventions are leading to improved 
outcomes of patients receiving HSCT but needing to go to PICU. Survival rates are now 
approaching up to 60%, better survival for those who receive only invasive ventilation and 
worse survival for those with multi organ failure[56].  
8.2. Other primary immunodeficiencies 
The results of transplant for other primary immunodeficiencies are historically not so good 
as those for patients with SCID but are improving over time[8]. This is likely due to a 
number of factors. Foremost is the adoption of stem cell transplant as a recognised therapy 
for the underlying condition. As transplant becomes an accepted treatment for a specific 
condition, patients with end organ disease undergo transplant, and some do not survive. 
Secondly, patients will need to undergo conditioning chemotherapy in order to prevent 
rejection of the graft and achieve donor chimerism and are therefore subject to the toxicities 
associated with conditioning. Thirdly, is the question of the optimum time to perform 
transplantation. Severe combined immunodeficiencies are usually fatal within the first 18 
months of life, patients with other primary immunodeficiencies live longer and can survive 
into adulthood, albeit with a deteriorating quality of life as they accumulate end organ 
damage secondary to infection and inflammatory complications of the underlying disease. 
Registry data has provided good quality information about long term prognosis for some of 
these disorders, even when appropriate antimicrobial prophylaxis is available, enabling 
parents, patients and physicians to make informed choices about timing of 
transplantation[6, 11, 57]. Most non-SCID PIDs are life limiting in the medium to long term, 
rather than fatal in the first few months of life. As with SCID, results of transplant are better 
if patients are transplanted whilst younger, without end organ damage. For those with XLP, 
survival from transplant is significantly better for patients who do not experience 
haemophagocytic lymphohistiocytosis[58]. In a similar fashion, for patients with chronic 
granulomatous disease, outcome is better in those that have not had significant fungal 
infection or inflammatory sequalae[24]. Thus transplantation at an early age before onset of 
complications gives the best chance of survival and cure but some families may prefer not to 
put a healthy child through transplant, rather monitoring them closely for significant 
deterioration and transplant at the first sign of trouble. It is advisable that searches for an 
appropriate donor are made soon after diagnosis so that transplantation can proceed 
quickly once the decision to transplant has been made.  
The amount of chimerism required to achieve cure depends on the underlying disease. 
Patients with CD40 ligand require only good T cell donor chimerism which will enable 
immunoglobulin class switching, whereas Wiskott Aldrich Syndrome patients with 
incomplete donor chimerism are much more likely to develop auto immune 
complications[20]. The cell lineage in which donor chimerism is required may not be 
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obvious. A patient with IPEX syndrome was cured although T cells appeared to be recipient, 
because on detailed study, the only donor cells were found to be the FOXP3+ cells[59], 
required to cure the condition. On the other hand, donor B cells are required in CgC or JAK-
3 deficient SCID to achieve independence from immunoglobulin substitution[51, 60], but 
recipient B cells are functional in SCID due to defects in IL7Ra. 
9. Complications post HSCT 
Complications following transplantation for primary immunodeficiency are similar to those 
for patients with malignancy. Infection through the transplant period is a risk, particularly 
when patients are aplastic (Figure 4). Any primary immunodeficiency patients may carry 
pre-existing infection (particularly viral infection) into transplant, as the underlying 
condition means that they are unable to clear infections effectively. Careful assessment of  
 
Figure 4.  
pre-existing infection needs to be made pre-transplant so that treatment can be optimised as 
patients begin transplant to reduce the risk of infectious complications. Pneumonitis, 
particularly at engraftment is a risk, especially in those with pre-existing viral pneumonitis 
at time of transplantation[61]. Nebulised steroids may improve the outcome in these 
patients. Acute and chronic graft versus host disease may be significant complications in 
primary immunodeficiency patients post transplant. Unlike patients with malignancy, graft 
versus host disease is not encouraged as there is no graft versus leukaemia benefit to be 
gained. Therefore HLA matching, T cell depletion where appropriate and Graft versus host 
disease prophylaxis with a calcineurine inhibitor (with or without additional 
MMF/steroids/Methotrexate) should be utilised. Staging and treatment of established graft 
versus host disease (Table 3) is as for other transplant patients - methylprednisoline 
 
Stem Cell Transplantation for Primary Immunodeficiency 19 
(2mg/kg) is standard first line treatment. If the patient fails to respond to this, then a variety 
of other agents may be tried including monoclonal antibodies such as infliximab, 
alemtuzimab, antithymocyteglobulin, mesenchymal stem cells and extra corporeal 
phototherapy but none have yet proven to be consistently effective. Veno occlusive disease 
is a risk factor particularly in those with osteopetrosis, with pre-existing liver disease or 
under going conditioning with busulphan or cyclophosphamide. Prophylaxis with 
defibrotide is effective at preventing veno-occlusive disease and treating if necessary[62]. 
Haemorrhagic cystitis is a rare complication following HSCT, associated with adenovirus or 
BK virus infection, associated with T cell depletion or prolonged immunosuppression. 
Treatment is as for patients undergoing HSCT for other indications[63].  
 
Stage Skin 
% body surface area 
Liver
Bilirubin μmol/l 
Gut
Diarrhoea vol. ml/kg/day 
(or if >50kg body weight) 
1 Maculopapular <25% 34-50 10-19.9 (or 500-1000ml/day) 
2 25-50% 51-100 20-30 
(or 1000-1500ml/day) 
3 Generalised erythema 101-255 >30
(or>1500ml/day) 
4 Exfoliation/vesicles >256 Severe abdo pain +/- ileus 
 
Grade Skin stage Liver stage Gut stage Clinical performance 
I 1-2 0 0 normal 
II 1-3 1 1 mild decrease 
III 2-3 2-3 2-3 marked decrease 
IV 2-4 2-4 2-4 incapacitated 
 
Adapted from Jacobsohn DA[69] 
Table 3. Staging of acute GVHD 
10. Post transplantation immuno-reconstitution 
Full immunoreconstitution can take up to 2 years post transplant. Most patients remain on 
immunoglobulin replacement for around 6 months post transplant or until evidence of 
immunoglobulin production (gauged by measuring IgM production). Ongoing 
immunosuppression or graft versus host disease will delay assessment of antibody 
production. Thymopoiesis can be measured by documenting an increase in recent thymic 
emigrants measured by TRECS or surrogate markers such as CD27 or CD31 on T cells. 
Thymopoiesis normally occurs around 120 days post transplant[64]. Graft versus host 
disease may impair or abrogate this process[65].  
Once immunoglobulin production is established, immunoglobulin replacement should be 
discontinued. After a wash out period of 3 months, primary vaccinations with non-live 
antigens can begin, having assessed base line specific antibody levels. The response to 
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vaccine antigens can be assessed once the primary vaccination schedule is complete. 
Vaccination with live vaccines such as MMR should only be considered once normal T cell 
proliferation has been demonstrated and an antibody response to the primary vaccination 
schedule has been confirmed. Prophylaxis against polysaccharide coated organisms should 
be continued for at least 2 years post transplant[66]. Patients should however have received 
the conjugated pneumococcal and meningococcal vaccines. Once the response to 
polysaccharide organisms has been demonstrated in those with normal splenic function, 
antibiotic prophylaxis can be discontinued. Patients should be monitored for evidence of 
endocrine dysfunction - particularly thyroid dysfunction[67]. Thyroid dysfunction occurs in 
up to 10% of post transplant patients. Usually this is hypothyroidism but more rarely 
hyperthyroidism has been described and each should be managed appropriately. In the long 
term there may be issues with fertility due to the conditioning regimens and patients should 
be counselled accordingly – referral to fertility clinics or endocrine specialists may be 
necessary. Growth is usually normal, and growth retardation due to the underlying illness 
may be reversed post transplant. Ongoing care of previous end organ damage such as 
bronchiectasis may require specialist input with regular monitoring of lung function and 
radiological changes. The quality of life post transplant has not been extensively assessed in 
primary immune deficiency patients. One study looking at the outcome of patients 
transplanted for severe primary immune deficiency demonstrated an increased risk of long 
term cognitive difficulties with associated emotional and behavioural difficulties. Specific 
genetic diagnosis and a severe clinical course were specifically associated with poor 
outcome[68]. Conversely a recent study looking at patients with CGD found significantly 
better quality of life skills in those who had undergone transplantation compared to those 
who were not transplanted, with the post transplant patients score similar to normal 
controls. As more patients survive the transplant procedure and a longer follow up is 
achieved further work will be needed in this area to determine quality of life.   
11. Future prospects  
Transplantation for primary immunodeficiency is a successful treatment leading to cure of 
disease and normal life quality for the majority of patients. Future work will need to address 
optimal timing of transplantation, which may be gauged as future registry data becomes 
available. Less damaging conditioning regimens, particularly for newborns identified with 
the newborn screening programmes will become important. Treosulfan, fludarabine 
containing regimens are less toxic than busulphan containing regimens but targeting 
conditioning using radiotherapy or monoclonal antibodies may play a great role in the 
future. Accelerating thymopoiesis and immuno-reconstitution will be important particularly 
when pre-existing viral infection is present. Agents including exogenous interleukin 7 or 
keratinous growth factor may have a role to play. Graft manipulation may improve 
outcomes for some patients -  better use of T cell depleted donors when no matched donors 
are available and particularly improving immune reconstitution through TCR alpha beta 
depletion may be appropriate. Expansion of stem cells in cord blood transplantation, the use 
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of multiple cords or the combined use of haplo-identical stem cells with an umbilical cord 
blood stem cell unit may also speed of immune reconstitution and lessen the risk from viral 
infection. Increased use of viral specific cytotoxic T cells will have a role to play. Finally 
better and more effective treatment of steroid resistant Graft versus host disease is needed 
and the use of extra corporeal phototherapy, the role of regulatory T cells and of 
mesenchymal stem cells needs to be explored.  
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